摘要
治疗满意度量表(TSS)是为评估男性勃起功能障碍(ED)患者及其性伴侣对ED治疗的满意度而制订的一个新量表。该自我报告式的调查问卷由四大部分组成:未治疗期的患者,治疗期的患者,未治疗期患者的性伴侣,以及治疗期患者的性伴侣。对以下6个方面进行评估:自信心、勃起的容易度、对勃起功能的满意度、性快感、对性高潮的满意度以及治疗满意度。TSS量表已经过多国有效性检验和心理学测验,被证明能可靠评价患者及其伴侣对ED治疗的满意度。在最近完成的一项双盲、多中心、平行组、灵活剂量的临床试验中,应用这个新的TSS量表比较了ED患者及其伴侣对伐地那非和安慰剂治疗的满意度。结果发现,伐地那非能显着改善勃起功能以及ED患者和伴侣的自信心、感知到的勃起容易度、性快感、对勃起功能、高潮和药物治疗的满意度。
The Treatment Satisfaction Scale （TSS） has been developed to assess various concepts related to erectile dysfunction （ED） treatment satisfaction in patients and their partners. The self-report questionnaire consists of 4 modules, unmedicated patient, medicated patient, unmedicated partner, and medicated partner modules, measuring a range of sexuality concepts considered important by ED patients and their partners including six domains： “Confidence”, “Ease with Erection”, “Erectile Function Satisfaction”, “ Pleasure from Sexual Activity” , “Satisfaction with Orgasms” , and “Satisfaction with Medication”. The TSS is an internationally valid, psychometrically sound instrument to assess patient and partner satisfaction with ED therapy. In a recent double-blind, muhicenter, parallel arms, flexible dose clinical trial, the TSS was used to compare patient and partner＇s satisfaction with vardenafil and plecobo therapy. The results demonstrated that vardenafil significantly improved not only erectile function, but also confidence, ease of erection, pleasure, and satisfaction with erectile function, orgasm and medication in men ED and their partners. These attributes are considered to be essential in the acceptance and continued use of PDE5 inhibitor therapy for ED.
出处
《中华男科学杂志》
CAS
CSCD
2005年第9期716-719,共4页
National Journal of Andrology
